{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:59:53Z","timestamp":1785182393784,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11427-025-3266-x","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:28:59Z","timestamp":1779067739000},"page":"2742-2753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer"],"prefix":"10.1007","volume":"69","author":[{"given":"Wei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"3266_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1758-2946-1-15","volume":"1","author":"Z Bikadi","year":"2009","unstructured":"Bikadi, Z., and Hazai, E. (2009). Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform 1, 15.","journal-title":"J Cheminform"},{"key":"3266_CR2","doi-asserted-by":"publisher","first-page":"e2206588119","DOI":"10.1073\/pnas.2206588119","volume":"119","author":"BP Brown","year":"2022","unstructured":"Brown, B.P., Zhang, Y.K., Kim, S., Finneran, P., Yan, Y., Du, Z., Kim, J., Hartzler, A.L., LeNoue-Newton, M.L., Smith, A.W., et al. (2022). Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. Proc Natl Acad Sci USA 119, e2206588119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3266_CR3","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-11-2353","volume":"18","author":"KP Chung","year":"2012","unstructured":"Chung, K.P., Wu, S.G., Wu, J.Y., Yang, J.C.H., Yu, C.J., Wei, P.F., Shih, J.Y., and Yang, P.C. (2012). Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res 18, 3470\u20133477.","journal-title":"Clin Cancer Res"},{"key":"3266_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ccell.2016.02.010","volume":"29","author":"SA Foster","year":"2016","unstructured":"Foster, S.A., Whalen, D.M., \u00d6zen, A., Wongchenko, M.J., Yin, J.P., Yen, I., Schaefer, G., Mayfield, J.D., Chmielecki, J., Stephens, P.J., et al. (2016). Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2. Cancer Cell 29, 477\u2013493.","journal-title":"Cancer Cell"},{"key":"3266_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2022.01.014","volume":"166","author":"LT Huang","year":"2022","unstructured":"Huang, L.T., Zhang, S.L., Han, C.B., and Ma, J.T. (2022). Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-treated advanced non-small-cell lung cancer. Lung Cancer 166, 9\u201316.","journal-title":"Lung Cancer"},{"key":"3266_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.lungcan.2014.09.014","volume":"86","author":"T Kaneda","year":"2014","unstructured":"Kaneda, T., Hata, A., Tomioka, H., Tanaka, K., Kaji, R., Fujita, S., Tomii, K., and Katakami, N. (2014). Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer 86, 213\u2013218.","journal-title":"Lung Cancer"},{"key":"3266_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/JTO.0b013e3182781e35","volume":"8","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi, S., Canepa, H.M., Bailey, A.S., Nakayama, S., Yamaguchi, N., Goldstein, M.A., Huberman, M.S., and Costa, D.B. (2013). Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8, 118\u2013122.","journal-title":"J Thorac Oncol"},{"key":"3266_CR8","doi-asserted-by":"publisher","first-page":"eaan6566","DOI":"10.1126\/scitranslmed.aan6566","volume":"9","author":"S Kohsaka","year":"2017","unstructured":"Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017). A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med 9, eaan6566.","journal-title":"Sci Transl Med"},{"key":"3266_CR9","doi-asserted-by":"publisher","first-page":"103996","DOI":"10.1016\/j.esmoop.2024.103996","volume":"9","author":"SH Lee","year":"2024","unstructured":"Lee, S.H., Menis, J., Kim, T.M., Kim, H.R., Zhou, C., Kurniawati, S.A., Prabhash, K., Hayashi, H., Lee, D.D.W., Imasa, M.S., et al. (2024). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer. ESMO Open 9, 103996.","journal-title":"ESMO Open"},{"key":"3266_CR10","doi-asserted-by":"publisher","first-page":"101834","DOI":"10.1016\/j.tranon.2023.101834","volume":"39","author":"Z Lu","year":"2024","unstructured":"Lu, Z., Yi, Y., Wang, L., Luo, Y., Luo, D., Xiong, L., Shu, Y., Luo, H., Li, J., Zhu, W., et al. (2024). Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors. Transl Oncol 39, 101834.","journal-title":"Transl Oncol"},{"key":"3266_CR11","doi-asserted-by":"crossref","unstructured":"Owen, D.H., Ismaila, N., Ahluwalia, A., Feldman, J., Gadgeel, S., Mullane, M., Naidoo, J., Presley, C.J., Reuss, J.E., Singhi, E.K., et al. (2025). Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.3. J Clin Oncol 43.","DOI":"10.1200\/JCO-24-02785"},{"key":"3266_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejca.2020.10.005","volume":"141","author":"X Peng","year":"2020","unstructured":"Peng, X., Long, X., Liu, L., Zeng, L., Yang, H., Jiang, W., Liao, D., Li, K., Wang, J., Lizaso, A., et al. (2020). Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. Eur J Cancer 141, 199\u2013208.","journal-title":"Eur J Cancer"},{"key":"3266_CR13","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D., J\u00e4nne, P.A., Cheng, Y., Yang, J.C.H., Yanagitani, N., Kim, S.W., Sugawara, S., Yu, Y., Fan, Y., Geater, S.L., et al. (2023). Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389, 1935\u20131948.","journal-title":"N Engl J Med"},{"key":"3266_CR14","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/sj.bjc.6601873","volume":"90","author":"M Ranson","year":"2004","unstructured":"Ranson, M. (2004). Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 90, 2250\u20132255.","journal-title":"Br J Cancer"},{"key":"3266_CR15","doi-asserted-by":"publisher","first-page":"102820","DOI":"10.1016\/j.critrevonc.2019.102820","volume":"146","author":"SE Rebuzzi","year":"2020","unstructured":"Rebuzzi, S.E., Alfieri, R., La Monica, S., Minari, R., Petronini, P.G., and Tiseo, M. (2020). Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol 146, 102820.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3266_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely, G.J., Wood, D.E., Ettinger, D.S., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., Bruno, D.S., Chang, J.Y., Chirieac, L.R., et al. (2024). Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 22, 249\u2013274.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3266_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"JP Robichaux","year":"2021","unstructured":"Robichaux, J.P., Le, X., Vijayan, R.S.K., Hicks, J.K., Heeke, S., Elamin, Y.Y., Lin, H.Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021). Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597, 732\u2013737.","journal-title":"Nature"},{"key":"3266_CR18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361, 958\u2013967.","journal-title":"N Engl J Med"},{"key":"3266_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cllc.2018.10.009","volume":"20","author":"S Rossi","year":"2019","unstructured":"Rossi, S., Toschi, L., Finocchiaro, G., Di Noia, V., Bonomi, M., Cerchiaro, E., Ceresoli, G.L., Beretta, G.D., D\u2019Argento, E., and Santoro, A. (2019). Impact of exon 19 deletion subtypes in EGFR-mutant metastatic non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors. Clin Lung Cancer 20, 82\u201387.","journal-title":"Clin Lung Cancer"},{"key":"3266_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S.V., Bell, D.W., Settleman, J., and Haber, D.A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169\u2013181.","journal-title":"Nat Rev Cancer"},{"key":"3266_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J.C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K.H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378, 113\u2013125.","journal-title":"N Engl J Med"},{"key":"3266_CR22","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","volume":"25","author":"A Truini","year":"2019","unstructured":"Truini, A., Starrett, J.H., Stewart, T., Ashtekar, K., Walther, Z., Wurtz, A., Lu, D., Park, J.H., DeVeaux, M., Song, X., et al. (2019). The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. Clin Cancer Res 25, 6382\u20136391.","journal-title":"Clin Cancer Res"},{"key":"3266_CR23","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","volume":"13","author":"IK van Alderwerelt van Rosenburgh","year":"2022","unstructured":"van Alderwerelt van Rosenburgh, I.K., Lu, D.M., Grant, M.J., Stayrook, S.E., Phadke, M., Walther, Z., Goldberg, S.B., Politi, K., Lemmon, M.A., Ashtekar, K.D., et al. (2022). Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nat Commun 13, 6791.","journal-title":"Nat Commun"},{"key":"3266_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1186\/s12885-021-08942-x","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Zheng, R., Hu, P., Zhang, Z., Shen, S., and Li, X. (2021). Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimertinib upon acquisition of T790M. BMC Cancer 21, 1215.","journal-title":"BMC Cancer"},{"key":"3266_CR25","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296\u2013W303.","journal-title":"Nucleic Acids Res"},{"key":"3266_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.34507","volume":"153","author":"SG Wu","year":"2023","unstructured":"Wu, S.G., Gow, C.H., Chen, Y.L., Liu, Y.N., Tsai, M.F., and Shih, J.Y. (2023). Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR. Int J Cancer 153, 352\u2013363.","journal-title":"Int J Cancer"},{"key":"3266_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11523-020-00722-0","volume":"15","author":"H Xu","year":"2020","unstructured":"Xu, H., Li, W., Yang, G., Li, J., Yang, L., Xu, F., Yang, Y., Ying, J., and Wang, Y. (2020). Heterogeneous response to first-generation tyrosine kinase inhibitors in non-small-cell lung cancers with different EGFR exon 19 mutations. Targ Oncol 15, 357\u2013364.","journal-title":"Targ Oncol"},{"key":"3266_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","volume":"13","author":"JCH Yang","year":"2012","unstructured":"Yang, J.C.H., Shih, J.Y., Su, W.C., Hsia, T.C., Tsai, C.M., Ou, S.H.I., Yu, C.J., Chang, G. C., Ho, C.L., Sequist, L.V., et al. (2012). Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 13, 539\u2013548.","journal-title":"Lancet Oncol"},{"key":"3266_CR29","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-12-1894","volume":"19","author":"P Yeh","year":"2013","unstructured":"Yeh, P., Chen, H., Andrews, J., Naser, R., Pao, W., and Horn, L. (2013). DNA-mutation inventory to refine and enhance cancer treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy. Clin Cancer Res 19, 1894\u20131901.","journal-title":"Clin Cancer Res"},{"key":"3266_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","volume":"125","author":"X Zhang","year":"2006","unstructured":"Zhang, X., Gureasko, J., Shen, K., Cole, P.A., and Kuriyan, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137\u20131149.","journal-title":"Cell"},{"key":"3266_CR31","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.21037\/tlcr-19-359","volume":"9","author":"C Zhao","year":"2020","unstructured":"Zhao, C., Jiang, T., Li, J., Wang, Y., Su, C., Chen, X., Ren, S., Li, X., and Zhou, C. (2020). The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer. Transl Lung Cancer Res 9, 1149\u20131158.","journal-title":"Transl Lung Cancer Res"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3266-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3266-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:02:03Z","timestamp":1785178923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3266-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3266"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3266-x","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. The study was executed according to the principles of the Declaration of Helsinki. Informed consent was obtained from each participant, and approval for the study protocol was obtained from the Institutional Review Board (NCC2023C-1089).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}